| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7946ec4f3ab0ccdf6d369bf5079567ea |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39541
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 |
| filingDate |
2010-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28296149485caefd429442c7de2d9b48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd3bdf0e773c19c26e3dfe4746822321
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_524c7f5e9a17b9c3b2578015c4debbba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ed5db1b2a7a348eaf0fecb5ad1b0ef6 |
| publicationDate |
2012-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20120083359-A |
| titleOfInvention |
Dosage regimens for the administration of EVCAMXCD3 bispecific antibodies |
| abstract |
The invention includes the steps of (a) continuous administration of a first dose of EpCAMxCD3 bispecific antibody for a first period of time, and then (b) continuous administration of a second dose of the antibody for a second period of time, wherein The second dose relates to a method (dosage regimen) for administering an EpCAMxCD3 bispecific antibody to a human patient in excess of the first dose. The methods of the invention (and also the dosage regimens of the invention) also alleviate and / or prevent mediated medical symptoms by treating EpCAM positive epithelial cancer cells in human patients or by continuous administration of EpCAMxCD3 bispecific antibodies in human patients. Suitable for The invention also relates to the use of an EpCAMxCD3 bispecific antibody for the preparation of a pharmaceutical composition for use in the method as defined in any of the claims. Also disclosed is a pharmaceutical package or kit comprising a first dose and a second dose as defined in the methods / dose regimens of the present invention. |
| priorityDate |
2009-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |